Skip to content [s] Site map [3] Home [1]
Graphic text

A Talented and Dedicated Research Team

At the heart of CHRISTUS Stehlin Foundation are dedicated scientists, administrative staff, and a hardworking board. The vision began with founder Dr. John S. Stehlin, Jr. and continues with President Robert F. (Bobby) Anderson, who has served as the Foundation’s Executive Director since 1991. All Stehlin staff members are dedicated to our mission, as evidenced by an average tenure of 16 years.

Noted Achievements

Stehlin physicians and scientists have shared their research discoveries and innovative treatment methods through more than 500 articles published in top national and international science and medical journals.

Stehlin scientists and staff are also active in community services and education. Researchers and other professionals speak on a variety of cancer related topics at local, national, and international meetings, private groups and functions, and radio and television talk shows throughout the year.

The Foundation has collaborated with a number of internationally renowned physicians and scientists at many of the world’s most prestigious public and private research facilities. Institutional collaborations include:


Our Team

Compared with other anticancer drugs at similar stages of development, camptothecins have demonstrated a much higher anticancer activity. Camptothecins can be envisioned as the ultimate anticancer drug when fully developed.”

National Academy of Science, 1995


Two Houston CHRISTUS Hospitals and Stehlin Soon to Join Houston Methodist

CHRISTUS Stehlin Foundation for Cancer Research will join CHRISTUS St. Catherine and CHRISTUS St. John in a new partnership with Houston Methodist.

Nearly 14 Million Cancer Survivors in U.S.

There are currently 13.7 million cancer survivors in the United States and the number is expected to rise by 31 percent to 18 million by 2022, according to a new report. >> Click article title for more.

'Watchful Waiting' Often Best for Older Kidney Cancer Patients

A new study suggests that sometimes simply watching and waiting is a safe alternative to surgery for older patients with small kidney tumors. A surgical oncologist said that the findings, "should allow clinicians and patients to feel more comfortable about surveillance, particularly for the 'oldest old' and those patients with multiple [other health conditions] that would make surgery especially high risk." >> Click on article title for more.

All News

Share this Page

Stay Connected

Button Button Button Button

Get Hope!

Sign up for our newsletter and updates.

CHRISTUS Stehlin Foundation for Cancer Research

10301 Stella Link Road, Suite A
Houston, Texas 77025-5447

Affiliates and Resources

Logo Logo Logo Logo Logo